switching from compounded tirzepatide to zepbound (Tirzepatide): A Q&A on the Mounjaro-Like Weight Loss Drug TrimRX | Can You Switch

Below is a framework comparing the strength of evidence across different clinical contexts where GLP-1 is used

Patient Impact and Safety Concerns The end of compounded semaglutide availability raises concerns about patient access and safety

The company had cut prices in November 2025 by 37% to expand the access of its chronic weight management therapy and counter Mounjaro which was launched in March 2025

Many also ignore basic FSSAI certifications, risking their health on imported, unverified grey-market products

They create multiple entry points based on the size and target area

BodySites Semaglutide Weight Loss Program provides a structured framework that supports these changes, offering patients the best chance for long-term success